Evidence map›Paper›PMID 29688608›Full record

ReviewOral diseases2019

Exosomal biomarkers in oral diseases.

Mohammad Hadavand, Sarfaraz Hasni

Abstract readReview
In one paragraph

Review in Oral diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Exosomes in the Oral and Maxillofacial Region.Journal of pharmacy & bioallied sciences · 2020
    Review
  4. Methods for extracellular vesicle isolation from cancer cells.Cancer drug resistance (Alhambra, Calif.) · 2020
    Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Mohammad HadavandNational Institutes of Health Clinical Center, National Institute of Dental and Craniofacial Research, Bethesda, Maryland.
Sarfaraz HasniNational Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, Maryland.ORCID http://orcid.org/0000-0002-4164-8837

Funding

Lupus Clinical TrialsZIAAR041232 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI HASNI, SARFARAZ · 2022 to 2025
$12.9M
Intramural NIH HHS Z99 AR999999Intramural NIH HHS ZIA AR041232NIH Clinical Center
6 · The paper itself

Abstract

Exosomes have emerged as novel nanovesicles that facilitate intracellular communication. The molecular content of exosomes is specific to their cell type of origin and reflective of the cells physiological status. Combined with their stability and accessibility in a variety of biofluids, exosomes may be used as biomarkers in a variety of diseases. Recent evidence suggests that exosomes have immunomodulatory functions that play a role in the severity and development of autoimmune disorders and cancers. This article focuses on the biomarker and therapeutic potential of exosomes for oral manifestation of autoimmune diseases and head and neck cancers.

Indexed as

Autoimmune DiseasesBiomarkersExosomesHead and Neck NeoplasmsHumansMouth DiseasesBiomarkersautoimmunityexosomehead and neck cancermiRNA

Identifiers

PMID29688608
PMCPMC13153726

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.